FS Development Corp (FSDC)

Etorro trading 970x250

About FS Development Corp

As of February 5, 2021, FS Development Corp. was acquired by Gemini Therapeutics, Inc., in a reverse merger transaction. FS Development Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the biotechnology sector. The company was founded in 2020 and is based in San Francisco, California. Address: 600 Montgomery Street, San Francisco, CA, United States, 94111

FS Development Corp News and around…

Latest news about FS Development Corp (FSDC) common stock and company :

Gemini Therapeutics Debuts as Publicly Traded Precision Medicine Company Focused on Age-Related Macular Degeneration
08 Feb, 2021 FinancialContent

Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the completion of its business combination with FS Development Corp. (Nasdaq: FSDC), a special purpose acquisition company (SPAC) sponsored by Foresite Capital. Gemini Therapeutics, Inc., the resulting combined company, will commence trading its shares today on the Nasdaq Global Market under the symbol “GMTX.” Gross proceeds from this transaction totaled approximately $216 million, which included funds held in FSDC’s trust account and the concurrent private investment in public equity (PIPE) financing. The shareholders of FSDC approved the transaction on February 3, 2021. The transaction was previously approved by Gemini Therapeutics’ shareholders. Gemini Therapeutics’ management team will continue to be led by Chief Executive Officer Jason Meyenburg.

Stocks That Hit 52-Week Highs On Tuesday
02 Feb, 2021 FinancialContent

On Tuesday morning, 172 companies achieved new highs for the year. Things to Consider: Alphabet (NASDAQ:GOOG) was the ...

FS Development Corp. Announces Effectiveness of Registration Statement for Proposed Business Combination with Gemini Special Meeting Scheduled for February 3, 2021
19 Jan, 2021 FinancialContent

FS Development Corp announced today that its registration statement on Form S-4 has been declared effective by the SEC.

Stocks That Hit 52-Week Highs On Monday
11 Jan, 2021 FinancialContent

This morning 127 companies reached new 52-week highs. Noteworthy Mentions: Johnson & Johnson (NYSE: JNJ) was the ...

Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration
15 Oct, 2020 FinancialContent

Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), and FS Development Corp. (Nasdaq: FSDC), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement. Upon closing of the transaction, the company will be renamed “Gemini Therapeutics, Inc.” (Combined Company) and will be led by Jason Meyenburg, Chief Executive Officer of Gemini. The Combined Company’s common stock is expected to be listed on Nasdaq.

FS Development Corp (FSDC) is a NASDAQ Common Stock listed in , ,

970x250